Bio-Gen company information, Employees & Contact Information

TruBeet by Bio-gen Extracts earns patent for innovation in nitrate nutrition Nutraceutical Business Review

Biogen Plans $2B Manufacturing Expansion at Research Triangle Park Genetic Engineering and Biotechnology News

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen Biogen

OmniActive sues Bio-gen Extracts for patent infringement NutraIngredients.com

Biogen (BIIB): Company Profile, Stock Price, News, Rankings Fortune

Bio-gen Extracts celebrates 25 years of pioneering wellness through nature, science, and purpose Nutraceutical Business Review

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square Biogen

Blue ocean market? Bio-gen studies lutein-zeaxanthin’s eye-brain benefits on teens NutraIngredients.com

Biogen groundbreaking stirs optimism in Kendall Square MIT News

Biogen Highlights the Potential of Felzartamab for a Range of Immune-Mediated Diseases Including Three Phase 3 Programs in Rare Kidney Diseases Biogen

Supplier update: Lonza, dsm-firmenich, Bio-gen in the spotlight NutraIngredients.com

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy Biogen

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients Biogen

Boomerang Employee: Why Shannon Found Her Way Back to Biogen Biogen

Learning and Leading: Lauren Love’s Co-op Experience Biogen

Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies Biogen

BIOGEN TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS MAY 1, 2025 Biogen

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences Biogen

Biogen Completes Acquisition of Human Immunology Biosciences Biogen

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases Biogen

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments Biogen

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease Biogen

Biogen Announces Changes to Its Board of Directors Biogen

Biogen Commits $2B To Expand US Drug Production Amid Tariff Talk BioSpace

2024 Corporate Responsibility Report Biogen

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results Biogen

Biogen Statement Regarding Updated ADUHELM® (aducanumab-avwa) Prescribing Information in US Biogen

Biogen Highlights Multiple Assets and Indications in Lupus Biogen

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025 Biogen

From small-town science curiosity to biotech leader Biogen

Biogen Completes Sale of Equity Stake in Biosimilar Joint Venture to Samsung Biologics for $2.3 Billion Biogen

Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease Biogen

Biogen Reports Progress on Corporate Responsibility Priorities Biogen

Biogen Ranked #1 Biotechnology Company by Dow Jones Sustainability World Index for an Industry Record 5th Time; Recognition Reflects Longstanding ESG Leadership Biogen

Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe Biogen

Swissmedic Grants Good Manufacturing Practice Multi-Product License to Biogen Biologics Facility in Solothurn, Switzerland Biogen

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA Biogen

Bio-gen Extracts Nutraceutical Business Review

Biogen Foundation Biogen

Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform Biogen

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 Biogen

Last year, Biogen’s CEO said no risky deals. Now, he’s ready to be bold Fierce Biotech

Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia Biogen

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS Biogen

Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression Biogen

New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease Biogen

Bio-gen Extracts’ Lute-gen supports visual health in high screen-time users – press release SupplySide Supplement Journal

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA Biogen

Alzheimer’s drug failure leaves Biogen in a precarious place statnews.com

Sage’s Search for Lifeline Ran Into Defiant Biogen CEO BioSpace

Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform Biogen

Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments Biogen

Biogen officially ends all AAV gene therapy work, prompting team restructure Fierce Biotech

Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research Biogen

Biogen Beefs Up Immuno Pipeline with Potential $1.8B HI-Bio Acquisition BioSpace

Despite a strong pharma shortlist, only Biogen, Organon place in Cannes Pharma Lions, as med techs take Gold, Grand Prix Fierce Pharma

Biogen and Samsung Bioepis’ BYOOVIZ™ (ranibizumab-nuna) Launches in the United States Biogen

Shaping Tomorrow: HR Expert Steers Cultural Evolution at Biogen Biogen

Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies Biogen

Biogen’s reckoning: How the Aduhelm debacle pushed a troubled company and its fractured leadership to the brink statnews.com

Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease Biogen

Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease Biogen

Beaten Down Biogen Stock Looks Attractive At Current Levels (NASDAQ:BIIB) Seeking Alpha

Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc. Biogen

Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec) Biogen

Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy Biogen

Biogen and C4 Therapeutics Enter into Strategic Collaboration to Discover and Develop Potential New Treatments for Neurological Conditions Biogen

5 Reasons Biogen’s Shares Have Dropped 36% in 2024 BioSpace

Biogen Announces Collaboration with University of Pennsylvania on Multiple Gene Therapy Programs Biogen

Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease Biogen

Biogen defends adalimumab biosimilar Imraldi with international team JUVE Patent

How a Premier U.S. Drug Company Became a Virus ‘Super Spreader’ (Published 2020) The New York Times

Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company Biogen

‘A very different and early stage’: 2 years ago, a Biogen conference in Boston sparked a COVID super-spreader MassLive

Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis Biogen

Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data Biogen

Biogen Stock Running in Place Despite Strong Quarter Investopedia

1 Year Later: The ‘Superspreader' Conference That Sparked Boston's COVID Outbreak NBC Boston

Expert Speak | Saif Mehkri, Founder & Director, Bio-gen Extracts Pvt. Ltd. Express Pharma

Growth Guardians | Saif Mehkri, Founder & Director, Bio-gen Extracts Pvt. Ltd. Express Pharma